Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)’s share price traded up 6% during mid-day trading on Thursday . The stock traded as high as $29.00 and last traded at $28.20, with a volume of 1,185,285 shares trading hands. The stock had previously closed at $26.60.

Several equities analysts have recently issued reports on the stock. Raymond James Financial, Inc. reissued a “strong-buy” rating and set a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. Cantor Fitzgerald reissued a “buy” rating and set a $50.00 price target on shares of Paratek Pharmaceuticals in a report on Wednesday, August 23rd. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, HC Wainwright boosted their price target on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Paratek Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $37.44.

The stock’s 50-day moving average is $21.96 and its 200 day moving average is $20.81. The stock’s market capitalization is $778.70 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million for the quarter, compared to analyst estimates of $7.50 million.

In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 3,800 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the transaction, the vice president now directly owns 69,500 shares in the company, valued at $1,638,810. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Douglas W. Pagan sold 4,595 shares of the stock in a transaction on Monday, June 19th. The stock was sold at an average price of $25.00, for a total value of $114,875.00. Following the transaction, the chief financial officer now owns 51,000 shares of the company’s stock, valued at $1,275,000. The disclosure for this sale can be found here. Insiders have sold 21,960 shares of company stock valued at $524,342 over the last quarter. Corporate insiders own 4.90% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc raised its stake in shares of Paratek Pharmaceuticals by 13.3% in the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock worth $144,000 after buying an additional 687 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth $172,000. Citigroup Inc. raised its stake in shares of Paratek Pharmaceuticals by 19,470.0% in the second quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 7,788 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth $200,000. Finally, Appleton Partners Inc. MA acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth $220,000. Institutional investors own 82.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Paratek Pharmaceuticals, Inc. (PRTK) Trading 6% Higher” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/02/paratek-pharmaceuticals-inc-prtk-trading-6-higher-2.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.